[ad_1]
The deal between the two companies is expected to be announced later Tuesday by US President Joe Biden, White House officials said.
In large clinical trials, the effectiveness of the Johnson & Johnson vaccine in preventing severe COVID-19 was 85.9%. In the United States, 81.7 percent. In South Africa and 87.6 percent. In Brazil.
Meanwhile, Merck dropped plans to produce its SARS-CoV-2 vaccine in January.
In the United States, a vaccine against coronavirus infection developed by Johnson & Johnson was approved for emergency use on February 27.
The single-dose vaccine is extremely effective in preventing acute COVID-19 infection, including newer strains, according to the US Food and Drug Administration (FDA) before approving the vaccine developed by Johnson & Johnson .
The European Medicines Agency (EMA) said on Tuesday that it would decide on March 11 whether Johnson & Johnson’s COVID-19 vaccine could be distributed in the European Union.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
